secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2026-09-04T20:05:30+00:00
Accession:  0001193125-26-383642
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences receives Nasdaq delisting notice for equity shortfall
-------------------------------------------------------------------------

- On Aug 31, 2026, Nasdaq notified Arcadia that stockholders' equity of $633,000 as of Jun 30, 2026, is below the $2.5M minimum required by Listing Rule 5550(b)(1).
- Company has until Oct 15, 2026 (45 days) to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension if plan accepted.
- If plan rejected, Arcadia can appeal to a Nasdaq Hearings Panel, which ordinarily stays suspension pending decision.
- Stock continues trading on Nasdaq Capital Market pending compliance review; no immediate delisting impact.
- CEO Thomas J. Schaefer signed the filing; company evaluating alternatives to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000119312526383642/0001193125-26-383642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000119312526383642/rkda-20260831.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-383642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer